Valproic Acid Antibody (803): sc-58068

Valproic Acid Antibody (803) is a mouse monoclonal IgG1 antibody that detects Valproic Acid in non-species reactive applications by enzyme-linked immunosorbent assay (ELISA). Anti-Valproic Acid antibody (803) is available in a non-conjugated form, providing researchers with a versatile tool for studying Valproic Acid, a fatty acid recognized for its role as an anticonvulsant and mood-stabilizing agent primarily used in the treatment of epilepsy and bipolar disorder, as well as for migraine headaches and schizophrenia. Valproic Acid′s mechanism of action is particularly noteworthy; Valproic Acid negatively impacts the inhibitory neurotransmission mediated by the neurotransmitter gamma-Aminobutyric acid (GABA) and serves as an inhibitor of histone deacetylase 1 (HDAC1), linking Valproic Acid to neuroprotective strategies in HIV therapy. Valproic Acid′s ability to elevate GABA levels in the brain or modify the characteristics of voltage-dependent sodium channels underscores Valproic Acid′s significance in neurological treatments. With a molecular weight of 144.211 g/mol and a half-life of 9-16 hours, Valproic Acid is primarily metabolized in the liver to its glucuronide conjugate, and common side effects include dyspepsia and weight gain. Valproic Acid monoclonal antibody (803) serves as an essential tool for researchers investigating the multifaceted roles of Valproic Acid in various therapeutic contexts.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

Valproic Acid Antibody (803) References:

1. Valproic acid inhibits corticotropin-releasing factor synthesis and release from the rat hypothalamus in vitro: evidence for the involvement of GABAergic neurotransmission.  |  Tringali, G., et al. 2004. J Psychiatry Neurosci. 29: 459-66. PMID: 15644987
2. Opposite effects of lithium and valproic acid on trophic factor deprivation-induced glycogen synthase kinase-3 activation, c-Jun expression and neuronal cell death.  |  Jin, N., et al. 2005. Neuropharmacology. 48: 576-83. PMID: 15755485
3. Valproic acid, in combination with all-trans retinoic acid and 5-aza-2'-deoxycytidine, restores expression of silenced RARbeta2 in breast cancer cells.  |  Mongan, NP. and Gudas, LJ. 2005. Mol Cancer Ther. 4: 477-86. PMID: 15767557
4. Valproic acid binding to human serum and human placenta in vitro.  |  Bailey, DN. and Briggs, JR. 2005. Ther Drug Monit. 27: 375-7. PMID: 15905810
5. Valproic acid: a potential role in treating latent HIV infection.  |  Routy, JP. Lancet. 366: 523-4. PMID: 16099272
6. Valproic acid inhibits growth, induces apoptosis, and modulates apoptosis-regulatory and differentiation gene expression in human thyroid cancer cells.  |  Shen, WT., et al. 2005. Surgery. 138: 979-84; discussion 984-5. PMID: 16360381
7. Behavioral effects of short-term administration of lithium and valproic acid in rats.  |  Tomasiewicz, HC., et al. 2006. Brain Res. 1093: 83-94. PMID: 16687130
8. Effects induced by the antiepileptic drug valproic acid upon the ionic currents recorded in rat neocortical neurons in cell culture.  |  Zona, C. and Avoli, M. 1990. Exp Brain Res. 81: 313-7. PMID: 2168843
9. Up-regulation of sodium channel subunit mRNAs and their cell surface expression by antiepileptic valproic acid: activation of calcium channel and catecholamine secretion in adrenal chromaffin cells.  |  Yamamoto, R., et al. 1997. J Neurochem. 68: 1655-62. PMID: 9084438